EA019258B1 - КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ - Google Patents

КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ Download PDF

Info

Publication number
EA019258B1
EA019258B1 EA201000633A EA201000633A EA019258B1 EA 019258 B1 EA019258 B1 EA 019258B1 EA 201000633 A EA201000633 A EA 201000633A EA 201000633 A EA201000633 A EA 201000633A EA 019258 B1 EA019258 B1 EA 019258B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
cancer
formula
composition
compositions
Prior art date
Application number
EA201000633A
Other languages
English (en)
Russian (ru)
Other versions
EA201000633A1 (ru
Inventor
Дэвид Лаури
Норберт Парро
Original Assignee
Фармасайкликс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармасайкликс, Инк. filed Critical Фармасайкликс, Инк.
Publication of EA201000633A1 publication Critical patent/EA201000633A1/ru
Publication of EA019258B1 publication Critical patent/EA019258B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201000633A 2007-10-16 2008-10-16 КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ EA019258B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98038607P 2007-10-16 2007-10-16
PCT/US2008/080221 WO2009052323A2 (en) 2007-10-16 2008-10-16 Manufacture, compositions and uses of coagulationfactor viia modulator

Publications (2)

Publication Number Publication Date
EA201000633A1 EA201000633A1 (ru) 2011-04-29
EA019258B1 true EA019258B1 (ru) 2014-02-28

Family

ID=40568072

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201000633A EA019258B1 (ru) 2007-10-16 2008-10-16 КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
EA201370191A EA201370191A1 (ru) 2007-10-16 2008-10-16 КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201370191A EA201370191A1 (ru) 2007-10-16 2008-10-16 КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ

Country Status (9)

Country Link
US (3) US8552046B2 (https=)
EP (2) EP2586794A3 (https=)
JP (2) JP5733744B2 (https=)
KR (1) KR20100093046A (https=)
CN (2) CN101861335B (https=)
CA (1) CA2702970A1 (https=)
EA (2) EA019258B1 (https=)
ES (1) ES2403413T3 (https=)
WO (1) WO2009052323A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2641058C1 (ru) * 2016-11-17 2018-01-15 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ профилактики венозной тромбоэмболии у больных раком шейки матки

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
KR100977903B1 (ko) 2004-06-02 2010-08-24 파마시클릭스, 인코포레이티드 Ⅶａ 인자 억제제
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
ES2403413T3 (es) 2007-10-16 2013-05-17 Pharmacyclics, Inc. Manufactura, composiciones y usos del modulador del factor de coagulación Vlla
US20140046277A1 (en) * 2011-04-15 2014-02-13 Gamma Therapeutics, Inc. Fast-clotting wound dressings
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
WO2015003025A1 (en) * 2013-07-05 2015-01-08 Mousa Shaker A NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3200804A4 (en) * 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
CN109627218B (zh) * 2018-11-27 2022-03-29 深圳市龙华区中心医院 一种抗凝小分子化合物及其应用和包含其的药物
CN116283896B (zh) * 2022-09-07 2024-10-29 广东晨康生物科技有限公司 一种具有pd-l1抑制活性的联苯类化合物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2093176C1 (ru) * 1992-12-16 1997-10-20 Левон Никитович Мкртчян Способ лечения рака молочной железы и рака тела матки
WO2004050637A2 (en) * 2002-12-03 2004-06-17 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
WO2004062661A1 (en) * 2003-01-08 2004-07-29 Axys Pharmaceuticals, Inc. 2-‘5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
WO2005118554A2 (en) * 2004-06-02 2005-12-15 Pharmacyclics, Inc. Factor viia inhibitor
WO2005121102A2 (en) * 2004-06-02 2005-12-22 Pharmacyclics, Inc. Factor viia inhibitor
RU2288746C2 (ru) * 2001-03-23 2006-12-10 Ново Нордиск А/С Игольчатая канюля, способ изготовления игольчатой канюли и использование игольчатой канюли
RU2297216C2 (ru) * 2002-04-08 2007-04-20 Эм-Джи-Ай Джи-Пи,Инк. Фармацевтические композиции, содержащие растворимые в воде пролекарства пропофола, и способы их применения

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO2000035886A2 (en) * 1998-12-18 2000-06-22 Axys Pharmaceuticals, Inc. (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
US6465503B2 (en) 2000-08-11 2002-10-15 Axys Pharmaceuticals, Inc. Selective urokinase inhibitors
US20020037912A1 (en) 2000-08-11 2002-03-28 Leahy Ellen M. Factor viia inhibitors
US20030114457A1 (en) * 2001-07-09 2003-06-19 Axys Pharmaceuticals, Inc. 2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AU2003215158A1 (en) * 2002-02-13 2003-09-04 Axys Pharmaceuticals, Inc. 2-(5-(5-carbamimidoyl-1h-heteroaryl))-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
ES2403413T3 (es) 2007-10-16 2013-05-17 Pharmacyclics, Inc. Manufactura, composiciones y usos del modulador del factor de coagulación Vlla
US20110299806A1 (en) * 2010-06-08 2011-12-08 Leonid Kashchenevsky Spindle, shaft supporting device and method of supporting a rotatable shaft

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2093176C1 (ru) * 1992-12-16 1997-10-20 Левон Никитович Мкртчян Способ лечения рака молочной железы и рака тела матки
RU2288746C2 (ru) * 2001-03-23 2006-12-10 Ново Нордиск А/С Игольчатая канюля, способ изготовления игольчатой канюли и использование игольчатой канюли
RU2297216C2 (ru) * 2002-04-08 2007-04-20 Эм-Джи-Ай Джи-Пи,Инк. Фармацевтические композиции, содержащие растворимые в воде пролекарства пропофола, и способы их применения
WO2004050637A2 (en) * 2002-12-03 2004-06-17 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
WO2004062661A1 (en) * 2003-01-08 2004-07-29 Axys Pharmaceuticals, Inc. 2-‘5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
WO2005118554A2 (en) * 2004-06-02 2005-12-15 Pharmacyclics, Inc. Factor viia inhibitor
WO2005121102A2 (en) * 2004-06-02 2005-12-22 Pharmacyclics, Inc. Factor viia inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ЧУЕШОВ В.И. и др., Промышленная технология лекарств, Харьков, НФАУ, МТК-Книга, 2002, т.2, с. 515-518, 520 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2641058C1 (ru) * 2016-11-17 2018-01-15 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ профилактики венозной тромбоэмболии у больных раком шейки матки

Also Published As

Publication number Publication date
ES2403413T3 (es) 2013-05-17
KR20100093046A (ko) 2010-08-24
US20140039022A1 (en) 2014-02-06
EP2586794A3 (en) 2013-07-17
CN101861335B (zh) 2013-09-04
EA201370191A1 (ru) 2014-05-30
JP2015157830A (ja) 2015-09-03
CN103705507A (zh) 2014-04-09
EA201000633A1 (ru) 2011-04-29
US8552046B2 (en) 2013-10-08
EP2209801A2 (en) 2010-07-28
WO2009052323A3 (en) 2009-09-11
WO2009052323A2 (en) 2009-04-23
CA2702970A1 (en) 2009-04-23
CN101861335A (zh) 2010-10-13
EP2586794A2 (en) 2013-05-01
EP2209801B1 (en) 2013-01-16
JP2011500717A (ja) 2011-01-06
US20130158089A1 (en) 2013-06-20
JP5733744B2 (ja) 2015-06-10
HK1147267A1 (en) 2011-08-05
US8748468B2 (en) 2014-06-10
US20100298396A1 (en) 2010-11-25
EP2209801A4 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
EA019258B1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
JP2023093684A (ja) 貧血治療のための組成物及び方法
US20080214555A1 (en) Use of ranolazine for the treatment of cardiovascular diseases
TW201818946A (zh) 包含至少一種氧化膽固醇硫酸鹽及至少一種聚烯烴二醇、羧甲基纖維素及聚氧甘油酯之組成物及彼等之使用方法
US20100035890A1 (en) Use of ranolazine for the treatment of cardiovascular diseases
ZA200406085B (en) A combination treatment for acute myocardial infarction.
US20090312340A1 (en) Use of ranolazine for the treatment of cardiovascular diseases
HU207455B (en) Method for producing pharmaceutical preparations suitable for treating postischemical heart-troubles containing captoprile and in given case thrombolitic agent
HK1147267B (en) Manufacture, compositions and uses of coagulationfactor viia modulator
HK1181783A (en) Manufacture, compositions and uses of coagulationfactor viia modulator
Angelkort et al. Hemodilution